Please assess the completion status of the following clinical trial:

Trial Title: A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female Chinese patients ≥ 18 years of age with diabetes mellitus and with HbA1c ≤10.0%~* Stable medication for diabetes within 3 months prior to Visit 1~* Visual impairment due to DME with BCVA score between 78 and 39 letters as measured by ETDRS-like charts at 4 meters~Key Exclusion Criteria:~* Stroke or myocardial infarction less than 3 months prior to screening visit~* Uncontrolled hypertension~* Active ocular infection or intraocular inflammation in any eye~* Treatment with any anti-angiogenic drugs within 3 months prior to baseline visit in any eye~* Active proliferative diabetic retinopathy in study eye~* Use of other investigational drugs within 30 days and systemic anti-VEGF drugs within 6 months prior to baseline visit~* Prior laser photocoagulation or intraocular procedure within 3 months prior to baseline in study eye~* History of intravitreal corticosteroid treatment in phakic study eye, and in aphakic or pseudophakic within 3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (RFB002) (Type: EXPERIMENTAL): 3 initial intravitreal injections to the study eye at Day 1, Month 1 and Month 2, followed by as-needed intravitreal injections of ranibizumab 0.5 mg guided by VA stabilization, plus sham laser
- Laser (Type: ACTIVE_COMPARATOR): Laser photocoagulation applied to the study eye at Day 1, followed by active laser photocoagulation at intervals no shorter than 3 months apart, plus sham injections

Based on this trial design, predict the completion outcome and termination type (if applicable).